The overarching goal of the Einstein/Rockefeller/CUNY CFAR (ERC-CFAR) Developmental Core is to support the career development of early stage investigators (ESIs) of the three participating institutions through an effective mentoring process coupled with a peer-reviewed Catalytic grants program and ongoing support for their scientific growth via their participation in programs specifically tailored for ESIs. The objectives of the ERC-CFAR Developmental core are centered on mentoring ESIs, catalyzing trans-institutional collaborative HIV/AIDS research in the ERC-CFAR, supporting Scientific Working Group (SWG) efforts to catalyze research in their topic areas, facilitating scientific communication among ERC-CFAR investigators and enhancing international HIV/AIDS research. We will accomplish these goals through the following six specific Aims.
In Aim 1 we will provide individually tailored mentoring to ESIs and facilitate their development into independently funded researchers by pairing ESIs with established investigators (EIs), by providing both individual and group- level mentoring to help them develop NIH K- or R- type grants and by assisting senior level ESIs with transition to an R01 funding.
In Aim 2, we will support ESIs engaged in AIDS research in the ERC-CFAR via catalytic and micro grants, which will also be used to promote trans-institutional collaborations and to support SWG priorities.
In Aim 3, we will stimulate intra- and trans-institutional, collaborative AIDS research at the participating institutions by awarding joint catalytic grants. We will proactively recruit non-AIDS EIs engaged in cutting edge research into AIDS research.
In Aim 4, we will facilitate scientific communication among ERC- CFAR investigators by organizing a bi-weekly Trans-institutional ERC-CFAR research seminar series and the biweekly Clinical AIDS Grand Rounds series both of which are simulcast to all three institutions, ERC-CFAR Invited Speaker Seminars and Annual ERC-CFAR Scientific Retreats to foster scientific interaction.
In Aim 5, we will promote AIDS Research in the ERC-CFAR via integration with other Einstein programs such as WIHS, the institutional AIDS T32 and the Geographic Medicine T32 programs and African HIV/AIDS research programs.
In Aim 6, we will facilitate and mentor ESIs in conducting community participatory and behavioral AIDS research via collaboration with the Behavioral Science Core.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI124414-04
Application #
9688460
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
4
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
081266487
City
Bronx
State
NY
Country
United States
Zip Code
10461
Grov, Christian; Jonathan Rendina, H; Patel, Viraj V et al. (2018) Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey. AIDS Behav 22:2743-2755
Cohen, Yehuda Z; Lorenzi, Julio C C; Krassnig, Lisa et al. (2018) Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med 215:2311-2324
Cohen, Yehuda Z; Lorenzi, Julio C C; Seaman, Michael S et al. (2018) Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol 92:
Cohen, Yehuda Z; Caskey, Marina (2018) Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS 13:366-373
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Liu, Yanyan; Ndumnego, Okechukwu C; Chen, Tingting et al. (2018) Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis. Pathogens 7:
Bar-On, Yotam; Gruell, Henning; Schoofs, Till et al. (2018) Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 24:1701-1707
Bachhuber, Marcus A; Nash, Denis; Southern, William N et al. (2018) Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial. BMJ Open 8:e019559
Patel, Viraj V; Ginsburg, Zoƫ; Golub, Sarit A et al. (2018) Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc 7:e11375
Marhefka, Stephanie L; Turner, DeAnne; Lockhart, Elizabeth et al. (2018) Meeting Our Patients ""Where They Are"": Video-Group Smoking Cessation for People Living With HIV. J Assoc Nurses AIDS Care 29:338-344

Showing the most recent 10 out of 27 publications